Filtered By:
Specialty: Cancer & Oncology
Condition: Hypertension
This page shows you your search results in order of relevance. This is page number 6.
Order by Relevance | Date
Total 198 results found since Jan 2013.
A phase II evaluation of sunitinib in the treatment of persistent or recurrent clear cell ovarian carcinoma: An NRG Oncology/Gynecologic Oncology Group Study (GOG-254).
CONCLUSION: Sunitinib demonstrated minimal activity in the second- and third-line treatment of persistent or recurrent clear cell ovarian carcinoma. ClinicalTrials.gov number, NCT00979992.
PMID: 29921512 [PubMed - as supplied by publisher]
Source: Gynecologic Oncology - June 16, 2018 Category: Cancer & Oncology Authors: Chan JK, Brady W, Monk BJ, Brown J, Shahin MS, Rose PG, Kim JH, Secord AA, Walker JL, Gershenson DM Tags: Gynecol Oncol Source Type: research
Unusual Techniques for Preserving Surgical and Oncologic Safety in Hepatectomy of Advanced Adrenal Malignancy with Vena Cava and Liver Invasion
We report herein three cases of major hepatectomy with IVC invasion and discuss several surgical tips.Patients and MethodsFrom March 2011 to February 2014, we retrospectively reviewed three cases of adrenal malignancy with liver and IVC invasion. Based on the severity of the malignant tumor, each case illustrates a different method to address surgical complications and maintain oncologic safety. Case 1: A 34-year-old woman was diagnosed with adrenocortical tumor during medical examination. Tumor invaded the right lobe of the liver and very close to the IVC. Fortunately, there was little thrombosis inside the IVC; we perfor...
Source: Annals of Surgical Oncology - September 6, 2018 Category: Cancer & Oncology Source Type: research
Efficacy of aflibercept with FOLFOX and maintenance with fluoropyrimidine as first ‑line therapy for metastatic colorectal cancer: GERCOR VELVET phase II study.
In this study, we evaluated the effects of aflibercept in first‑line therapy with FOLFOX followed by maintenance with fluoropyrimidine. VELVET was a prospective, single‑arm multicenter phase II study (completed). Patients with previously untreated, unresectable, evaluable or measurable mCRC, with an age ≥18 years, and an ECOG performance status of 0‑2 received 6 cycles of modified FOLFOX7 (5‑FU/folinic acid and oxaliplatin) with aflibercept at 4 mg/kg every 2 weeks followed by maintenance therapy with fluoropyrimidine with aflibercept until disease progression or limiting toxicity. The reintroduction of oxa...
Source: International Journal of Oncology - February 1, 2019 Category: Cancer & Oncology Authors: Chibaudel B, Bachet JB, André T, Auby D, Desramé J, Deplanque G, Lecaille C, Louvet C, Tournigand C, Lebrun-Ly V, Dauba J, Lledo G, Garcia ML, Dubreuil O, Hamed NB, Meurisse A, Larsen AK, Tijeras-Raballand A, Bonnetain F, De Gramont A Tags: Int J Oncol Source Type: research
Cardiac Complications in the Adult Bone Marrow Transplant Patient
AbstractPurpose of ReviewDue to advancements in oncologic treatment strategies and techniques, the number of survivors who have undergone hematopoetic stem cell transplant (HCT) continues to increase in the United States; this number is projected to reach 502,000 by the year 2030. There is significant interest within the field of cardio-oncology to identify cardiotoxicity and cardiovascular disease in the HCT population. Epidemiologic studies analyzing both short- and long-term cardiovascular effects, risk stratification modeling, cardioprotective strategies, and expert consensus documents for cardiotoxicity surveillance r...
Source: Current Oncology Reports - March 1, 2019 Category: Cancer & Oncology Source Type: research
Is androgen deprivation therapy associated with cerebral infarction in patients with prostate cancer? A Korean nationwide population ‐based propensity score matching study
ConclusionThis nationwide population ‐based study revealed that ADT was not associated with cerebral infarction after adjusting for potential confounders.
Source: Cancer Medicine - June 9, 2019 Category: Cancer & Oncology Authors: Bum Sik Tae,
Byeong Jo Jeon,
Hoon Choi,
Jae Hyun Bae,
Jae Young Park Tags: ORIGINAL RESEARCH Source Type: research
Prevalence of cardiovascular disease and risk factors, quality of life, and health behaviors of cancer survivors and their spouses: findings from MEPS
ConclusionsCompared to the general population, cancer survivors are at higher risk for CVD, report worse physical QOL, and, along with their spouses, more frequently receive certain preventive health care services.Implications for Cancer SurvivorsThere is a need for intervention to more fully engage cancer survivors and spouses in lifestyle behavior change associated with decreased CVD and related risk factors and improved QOL.
Source: Journal of Cancer Survivorship - August 21, 2019 Category: Cancer & Oncology Source Type: research
589PFluoropyrimidine-induced cardiotoxicity in colorectal cancer patients: Preliminary data from the prospective observational CHECKPOINT trial (NCT02665312)
ConclusionsA high incidence of CV events, with no apparent correlation with CV comorbidities or risk factors, was observed. Prompt identification and treatment of CV events allowed most pts to complete the treatment with FP.Clinical trial identificationNCT02665312.Legal entity responsible for the studyThe authors.FundingHas not received any funding.DisclosureM. Aglietta: Advisory / Consultancy: Bristol-Myers Squibb; Advisory / Consultancy: Merck; Advisory / Consultancy: Roche. All other authors have declared no conflicts of interest.
Source: Annals of Oncology - October 1, 2019 Category: Cancer & Oncology Source Type: research
Safety lead-in of the MEK inhibitor trametinib in combination with GSK2141795, an AKT inhibitor, in patients with recurrent endometrial cancer: An NRG Oncology/GOG study.
CONCLUSION: The combination of trametinib and GSK2141795 had high levels of toxicity in endometrial cancer at the previously RP2D but was tolerable at a reduced dose. Due to insufficient preliminary efficacy at a tolerable dose, the Phase II study was not initiated.
PMID: 31623857 [PubMed - as supplied by publisher]
Source: Gynecologic Oncology - October 14, 2019 Category: Cancer & Oncology Authors: Westin SN, Sill MW, Coleman RL, Waggoner S, Moore KN, Mathews CA, Martin LP, Modesitt SC, Lee S, Ju Z, Mills GB, Schilder RJ, Fracasso PM, Birrer MJ, Aghajanian C Tags: Gynecol Oncol Source Type: research
Factors Associated with Participation in Stool Based Colorectal Screening in Brunei Darussalam.
CONCLUSIONS: Our study showed that older age and professional employment status were significantly associated with willingness to participate in a stool based CRC screening.
PMID: 32856849 [PubMed - as supplied by publisher]
Source: Asian Pacific Journal of Cancer Prevention - August 29, 2020 Category: Cancer & Oncology Tags: Asian Pac J Cancer Prev Source Type: research
Healthcare fragmentation and cardiovascular risk control among older cancer survivors in the Reasons for Geographic And Racial Differences in Stroke (REGARDS) study
ConclusionsMore fragmented care was associated with worse glycemic control among cancer survivors with diabetes who reported excellent, very good, or good health. Associations were not observed for control of hypertension or hyperlipidemia.Implications for Cancer SurvivorsReducing fragmentation may support glucose control among survivors with diabetes.
Source: Journal of Cancer Survivorship - September 7, 2020 Category: Cancer & Oncology Source Type: research
Impact of the preoperative body mass index on the postoperative outcomes in patients with completely resected non-small cell lung cancer: A retrospective analysis of 16,503 cases in a Japanese Lung Cancer Registry Study
Obesity is responsible for multiple chronic diseases, including type 2 diabetes, hypertension, coronary artery disease, stroke, and several types of cancer [1]. The body mass index (BMI) —as an easy-to obtain, acceptable proxy for thinness and fatness—has been found to be associated with health risk and death in many populations. According to the World Health Organization definition, the normal range of BMI is defined as 18.5 to
Source: Lung Cancer - September 18, 2020 Category: Cancer & Oncology Authors: Koichi Fukumoto, Shoichi Mori, Yasushi Shintani, Jiro Okami, Hiroyuki Ito, Takashi Ohtsuka, Shinichi Toyooka, Takeshi Mori, Shun-ichi Watanabe, Hisao Asamura, Masayuki Chida, Hiroshi Date, Shunsuke Endo, Takeshi Nagayasu, Ryoichi Nakanishi, Etsuo Miyaoka, Source Type: research
Clinical significance of hypertension in patients with different types of cancer treated with antiangiogenic drugs
Oncol Lett. 2021 Apr;21(4):315. doi: 10.3892/ol.2021.12576. Epub 2021 Feb 23.ABSTRACTHypertension is a common comorbidity in patients receiving antiangiogenic therapy. Prior studies have reported worsening or new-onset hypertension as an adverse event of antiangiogenetic therapy, which can be managed by dose reduction or discontinuation of the culprit medication. By contrast, other studies have found that the occurrence of hypertension is a potential biomarker associated with greater efficacy of antiangiogenic therapy and predicts improved survival. At present, there is no consensus on the effects of hypertension in patien...
Source: Oncology Letters - March 11, 2021 Category: Cancer & Oncology Authors: Mei Dong Rujian Wang Ping Sun Dongxia Zhang Zhenzhen Zhang Jing Zhang Gary Tse Lin Zhong Source Type: research
